Evidence — Semax
peptide · asset evidence level: emerging
Evidence quality breakdown (linked documents)
expert_opinion: 9clinical: 1
Linked source documents (10)
- Semax — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Selank — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- Oxytocin Acetate — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- GHK-Cu — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- DSIP — Peptide Dosing Protocols reference (patient_education · expert_opinion)
- ARA-290 — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- SS-31 — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Semax — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Selank — Peptide Protocol Wiki reference (patient_education · expert_opinion)
- Semax: Mechanistic Overview (internal_protocol · clinical)
Provider dosing references (Stage 9, source-attributed)
300-600 mcg intranasally daily (or 1-3 drops/nostril of 0.1% solution) — Practitioner Peptide Dosing Reference (commonly published ranges)
200-600 mcg per dose (0.1% solution) for nootropic use; 3-6 mg per dose (1% solution) for stroke — Peptide Protocol Wiki (peptideprotocolwiki.com)
Standard: 0.6 to 1.5 mg/day · Low: sub-milligram per administration · High: up to ~1 mg/kg — Peptide Dosing Protocols (peptidedosingprotocols.com)
Dosing claims (65) · Safety claims (34)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.